TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse ...

TransCode Therapeutics (NASDAQ:RNAZ) will execute its previously announced 1-for-33 reverse stock split on Dec. 4, 2024. The company’s common stock is expected to begin trading on a split-adjusted ...

As previously announced, the 1-for-33 reverse stock split will automatically convert thirty-three current shares of TransCode’s common stock into one new share of common stock. No fractional shares ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

TransCode Therapeutics (RNAZ) has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash proceeds are expected to be approximately $8M before ...

TransCode Therapeutics, Inc. BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using ...

https://www.tipranks.com/news/company-announcements/enanta-pharmaceuticals-reduced-reporting-potential-impact-on-investor-appeal-and-stock-volatility TransCode ...

Transcode Therapeutics shares are trading lower by 11% to 34 cents Monday afternoon. The company announced its Board's approval of a 1-for-33 reverse stock split. What Else: Approved by ...

(RTTNews) - TransCode Therapeutics, Inc. (RNAZ), a company focused on cancer treatment using RNA therapeutics, said on Monday that its Board has approved a 1-for-33 reverse stock split. This move ...

In connection with the reverse stock split, the Company's CUSIP number will change to 89357L402 as of 12:01 a.m. Eastern Standard Time on December 4, 2024. About TransCode Therapeutics TransCode ...

TransCode’s common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on December 4, 2024, under the current trading symbol, “RNAZ.” ...

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to ...